CURE

FDA Approves Revuforj for R/R NPM1-Mutant AML

The U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib), which is a menin inhibitor, for the treatment ...
Targeted Oncology

Considering the Evolution of ARPI Combination Therapy in mHSPC

Combinations of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) are the accepted ...
Healio

Tumor board aims to treat cancer pain with same urgency as the malignancy

Tumor boards are an invaluable tool to share knowledge and ensure optimal treatment for people with cancer.The conversations ...
The American Journal of Managed Care

Latest NCCN Guidelines on the Standard of Care for Patients With AML

Panelists discuss how current NCCN guidelines emphasize the importance of treating AML at experienced centers with proper ...
GlobalData on MSN

GSK’s Blenrep gains FDA approval for myeloma treatment

The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A ...
Targeted Oncology

Poll Responses Show Preference Among Expanding Relapsed CLL Therapies

To understand treatment patterns and preferences, a series of expert-led Case-Based Roundtable events were conducted over the ...
TipRanks on MSN

Syndax Pharmaceuticals Gains FDA Approval for Revuforj

The latest update is out from Syndax Pharmaceuticals ( (SNDX) ).
The Manila Times

FDA approves Roche’s Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study1First and only combination therapy for the first-line maintenance ...